Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com
Patritumab Deruxtecan Elicits Durable Responses in EGFR-Mutated NSCLC
September 10th 2023Patritumab deruxtecan displayed clinically meaningful and durable efficacy in patients with advanced EGFR-mutated non–small cell lung cancer who experienced progression following treatment with an EGFR-directed TKI and platinum-based chemotherapy.
Read More
Without a plethora of randomized and historic data to compare treatments, selection and sequencing strategies for patients with relapsed/refractory multiple myeloma must balance a multitude of factors, including adverse effect profiles, disease resistance mechanisms, and more.
Read More
Ponatinib Increases MRD-Negative CR Rate in Ph+ ALL
September 6th 2023The addition of the TKI ponatinib to reduced-intensity chemotherapy led to an increase in minimal residual disease-negative complete remission rate at the end of induction compared with imatinib among patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Read More
Patients with essential thrombocythemia and polycythemia vera who also had arterial hypertension experienced a higher cumulative incidence of thrombotic adverse effects compared with those without hypertension and fewer thrombotic complications following treatment with renin angiotensin system inhibitors.
Read More
Divarasib Displays Early-Phase Activity in KRAS G12C–Mutant Solid Tumors
September 5th 2023Treatment with the KRAS G12C inhibitor divarasib (formerly GDC-6036) led to durable responses with a tolerable safety profile in patients with a variety of solid tumors harboring a KRAS G12C mutation.
Read More
Encorafenib/Binimetinib Combo Highlights Novel Therapies for BRAF V600+ NSCLC
August 31st 2023Corey J. Langer, MD, outlines the prevalence of BRAF mutations in NSCLC and looked ahead to where the development pipeline of agents for the treatment of patients with BRAF-mutated NSCLC is headed.
Read More
Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma
August 29th 2023The addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy.
Read More
Subcutaneous Trastuzumab Proves Safe and Tolerable in HER2+ Metastatic Breast Cancer
August 28th 2023The safety profile of subcutaneous trastuzumab was consistent with the known profile of intravenous administration of the agent and there were no new concerns related to prolonged exposure in patients with HER2-positive metastatic breast cancer.
Read More
Postoperative ctDNA Provides Prognostic Value for DFS Outcomes in CRC
August 26th 2023Circulating tumor DNA status at the time of postoperative minimal residual disease assessment was found to be a prognostic factor for disease-free survival in patients with radically resected stage II to IV colorectal cancer.
Read More
Erdafitinib Elicits Responses in FGFR-altered Solid Tumors
August 23rd 2023Treatment with erdafitinib resulted in clinical benefit for patients with advanced solid tumors harboring susceptible FGFR alterations who had exhausted all other treatment options, meeting the primary end point of overall response rate of the phase 2 RAGNAR trial.
Read More
Avelumab Increases PFS Rates in dMMR/MSI Metastatic CRC
August 18th 2023Patients with mismatch repair–deficient and/or microsatellite instability metastatic colorectal cancer experienced a progression-free survival benefit with longer disease control following treatment with avelumab compared with standard second-line chemotherapy.
Read More
GVAX Cancer Vaccine Plus Nivolumab and Urelumab Elicits Early Efficacy in Pancreatic Adenocarcinoma
August 14th 2023Treatment with the GVAX pancreatic cancer vaccine plus nivolumab and urelumab increased the presence of intratumoral activated cytotoxic T cells and showed early signs of efficacy in patients with resectable pancreatic adenocarcinoma.
Read More
Kirtane Highlights Uniqueness of Solid Tumor CAR T-Cell Agent A2B530
August 9th 2023Kedar Kirtane, MD, speaks on the unique mechanism of action of A2B530 and how the agent could represent a huge leap forward in the application of CAR T-cell agents for patients with solid tumors if the EVEREST-1 study proves to be positive.
Read More
Treatment with intermittent or continuous doses of relacorilant in combination with nab-paclitaxel resulted in an overall survival benefit compared with nab-paclitaxel monotherapy, but failed to demonstrate an improvement in progression-free survival in patients with recurrent, platinum-resistant ovarian cancer.
Read More
Pembrolizumab Generates Sustained Responses in Relapsed/Refractory PMBCL
August 5th 2023Pembrolizumab produced sustained antitumor activity in patients with relapsed/refractory primary mediastinal large B-cell lymphoma, according to data from the final analysis of the phase 2 KEYNOTE-170 trial.
Read More
Gilteritinib/Chemotherapy Combination Safe and Effective in Newly Diagnosed AML
August 3rd 2023The addition of the type 1 FLT3 inhibitor gilteritinib to induction and consolidation chemotherapy, followed by maintenance gilteritinib monotherapy, was safe and tolerable with promising initial efficacy in patients with newly diagnosed acute myeloid leukemia.
Read More
Time to Treatment Initiation Affected by Demographics, Socioeconomics in Solid Tumors
August 2nd 2023Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.
Read More
Mitomycin Gel May Have a Place in Chemo-Ablative Cytoreduction of Higher-Volume, Low-Grade UTUC
August 1st 2023Patients with low-grade upper tract urothelial carcinoma experienced similar rendered disease free rates, regardless of surgery type or tumor volume, following treatment with mitomycin for pyelocalyceal solution.
Read More
Novel Program Provides Avenue for Increased Biosimilar Uptake, Reduced Cost
July 27th 2023The implementation of a pharmacist-driven biosimilar substitution program across American Oncology Network institutions resulted in increased uptake of biosimilar agents as well as financial savings for payers, patients, and providers.
Read More
Varied levels of compliance were observed in terms of using validated quality indicators to determine the quality of active surveillance for patients with low-risk prostate cancer, according to findings from a population-based study published in the Journal of the Comprehensive Cancer Network.
Read More
DecisionDx-Melanoma 31-Gene Expression Profile Test Stratifies Patients With Cutaneous Melanoma
July 17th 2023The DecisionDx-Melanoma 31-gene expression profile test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients.
Read More